Curaleaf HoldingsCURLF +3.19%67 EV-to-EBITDA is 14.86 as of Jul. 08, 2026, which is 21% below its 10-year median of 18.91. GuruFocus rates CURLF with a GF Score™ of 67/100 and a GF Value™ of $7.98 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 740 Drug Manufacturers companies, Curaleaf Holdings ranks worse than 55.95% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Curaleaf Holdings's enterprise value is $3,387 Mil.
Curaleaf Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $228 Mil. Therefore, Curaleaf Holdings's EV-to-EBITDA for today is 14.86.
The historical rank and industry rank for Curaleaf Holdings's EV-to-EBITDA or its related term are showing as below:
CURLF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.13 Med: 18.91 Max: 541.85
Current: 14.86
During the past 12 years, the highest EV-to-EBITDA of Curaleaf Holdings was 541.85. The lowest was -132.13. And the median was 18.91.
CURLF's EV-to-EBITDA is ranked worse than 55.95% of 740
companies
in the Drug Manufacturers industry
Industry Median: 12.955
vs CURLF: 14.86
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Curaleaf Holdings's PE Ratio (TTM) for today is calculated as:
Curaleaf Holdings's share price for today is $9.70.
Curaleaf Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.607.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Curaleaf Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's EV-to-EBITDA falls into.
Curaleaf Holdings's current Enterprise Value is $3,387 Mil.
Curaleaf Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $228 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curaleaf Holdings (CURLF) has a EV-to-EBITDA of 14.86 as of Jul. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Curaleaf Holdings. This is 21% below median its historical median of 18.91. According to the industry distribution chart, Curaleaf Holdings ranks #414 out of 740 companies in the Drug Manufacturers industry, placing it in the top 55.9%.
Is Curaleaf Holdings' EV-to-EBITDA too high?
Curaleaf Holdings' current EV-to-EBITDA of 14.86 is 21% below median its 10-year median of 18.91. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Curaleaf Holdings' value of 14.86 is 14.7% above this industry median. Based on the distribution chart, Curaleaf Holdings ranks #414 out of 740 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curaleaf Holdings has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #414 out of 740 companies for EV-to-EBITDA. This places Curaleaf Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. Curaleaf Holdings' value of 14.86 is 14.7% above this benchmark. While the company's 10-year median is 18.91 vs. the industry median of 12.96, Curaleaf Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current EV-to-EBITDA of 14.86 is 14.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Curaleaf Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current EV-to-EBITDA is 14.86, which is 21% below median its own 10-year median of 18.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.98, compared to a current price of $9.70 — trading 21.6% above its estimated fair value. The current EV-to-EBITDA is 14.86, which is 21% below median its 10-year median of 18.91 and 14.7% above the Drug Manufacturers industry median of 12.96. Curaleaf Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current EV-to-EBITDA is 14.86 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $9.70 is trading 21.6% above its estimated GF Value™ of $7.98.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLF:
EV-to-EBITDA: 14.86 (21% below median its 10-year median of 18.91)
GF Value™: $7.98 vs. price of $9.70 (21.6% above fair value)
Industry Position: 14.7% above the Drug Manufacturers median (#414 of 740)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
67GF Score
Get the complete analysis for CURLF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
